New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1
ACS Chemical Biology · 19.05.2023 · 18 (5) · 1101-1114
DOI: 10.1021/acschembio.2c00805 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 19.04.2023. Verfasst von M Merced Malabanan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United …. Hauptthemen laut MEDLINE: Gene Expression Regulation, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHGRI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Nuclear receptor liver receptor homolog-1 (LRH-1, NR5A2) is a lipid-regulated transcription factor and an important drug target for several liver diseases. Advances toward LRH-1 therapeutics have been driven recently by structural biology, with fewer contributions from compound screening. Standard LRH-1 screens detect compound-induced interaction between LRH-1 and a transcriptional coregulator peptide, an approach that excludes compounds that regulate LRH-1 through alternative mechanisms. Here, we developed a FRET-based LRH-1 screen that simply detects compound binding to LRH-1, applying it to discover 58 new compounds that bind the canonical ligand-binding site in LRH-1 (2.5% hit rate), also supported by computational docking. Four independent functional screens identified 15 of these 58 compounds to also regulate LRH-1 function in vitro or in living cells. Although one of these 15 compounds, abamectin, directly binds LRH-1 and regulates full-length LRH-1 in cells, abamectin failed to regulate the isolated ligand-binding domain in standard coregulator peptide recruitment assays using PGC1α, DAX-1, or SHP. Abamectin treatment of human liver HepG2 cells selectively regulated endogenous LRH-1 ChIP-seq target genes and pathways associated with known LRH-1 functions in bile acid and cholesterol metabolism. Thus, the screen reported here can discover compounds not likely to have been identified in standard LRH-1 compound screens but which bind and regulate full-length LRH-1 in cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
- Department of Biochemistry and Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
ORCID-Profile: Abigail R Orun, Raymond D Blind
Förderung
- NIDDK NIH HHS
- NHGRI NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- Vanderbilt University
- National Human Genome Research Institute
- American Cancer Society
- National Institutes of Health
Zitieren
APA
Malabanan, M. M., Chapagain, P., Haratipour, Z., Choi, W. J., Orun, A. R., & Blind, R. D. (2023). New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1. ACS Chemical Biology, 18(5), 1101-1114. https://doi.org/10.1021/acschembio.2c00805
Vancouver
Malabanan MM, Chapagain P, Haratipour Z, Choi WJ, Orun AR, Blind RD. New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1. ACS Chemical Biology. 2023;18(5):1101-1114. doi:10.1021/acschembio.2c00805
BibTeX
@article{Malabanan2023,
author = {Malabanan, M Merced and Chapagain, Pratima and Haratipour, Zeinab and Choi, Woong Jae and Orun, Abigail R and Blind, Raymond D},
title = {New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1},
journal = {ACS Chemical Biology},
year = {2023},
volume = {18},
number = {5},
pages = {1101--1114},
doi = {10.1021/acschembio.2c00805}
}
EUVIMED